PDLIM1 and hepatocellular carcinoma: In hepatocellular carcinoma, PDLIM1 competitively binds to ACTN4, disrupting the interaction between ACTN4 and F-actin, thereby activating the Hippo pathway and inhibiting metastasis [11].